ARQULE
ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcrip... tion Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).
ARQULE
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
1993-01-01
Address:
Woburn, Massachusetts, United States
Country:
United States
Website Url:
http://www.arqule.com
Total Employee:
11+
Status:
Closed
Contact:
781-994-0300
Email Addresses:
[email protected]
Total Funding:
183.2 M USD
Technology used in webpage:
Domain Not Resolving IPv6 Cloudflare Microsoft DigiCert SSL Akamai Hosted
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
SpeciGen Inc.
SpeciGen is a developmental biotechnology company, engages in the design and development of protein cages that contain samples of cancer.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2003-07-18 | Cyclis Pharmaceuticals | Cyclis Pharmaceuticals acquired by ArQule | 25 M USD |
| 2001-01-22 | Camitro | Camitro acquired by ArQule | 106.2 M USD |
Investors List
Pontifax
Pontifax investment in Post-IPO Equity - ArQule
Atlas Venture
Atlas Venture investment in Seed Round - ArQule
More informations about "ArQule"
ArQule - Crunchbase Company Profile & Funding
ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employsSee details»
ArQule - Contacts, Employees, Board Members, Advisors & Alumni
ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employsSee details»
ArQule - Org Chart, Teams, Culture & Jobs | The Org
View ArQule's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Home - ARCQE
The ARCQEtivities portal creates a world of fun for you and your family with a wide range of hands-on activities designed to spark growth through play. As your go-to platform for …See details»
Merck Completes Acquisition of ArQule - Merck.com
Jan 16, 2020 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of …See details»
ArQule, Inc. - VentureRadar
ArQule is an American biotechnology company that researches, develops, and commercializes broadly effective cancer drugs with reduced toxicities compared to conventional cancer …See details»
ArQule Company Profile 2024: Valuation, Investors, Acquisition
Information on acquisition, funding, cap tables, investors, and executives for ArQule. Use the PitchBook Platform to explore the full profile.See details»
Merck to Acquire ArQule, Advancing Leadership in Oncology
Dec 9, 2019 Merck (NYSE: MRK), known as MSD outside the United States and Canada, and ArQule, Inc. (Nasdaq: ARQL) today announced that the companies have entered into a …See details»
Merck Begins Tender Offer to Acquire ArQule
Dec 17, 2019 Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding …See details»
ArQule CEO and Key Executive Team | Craft.co
ArQule's CEO is Paolo Pucci. Other executives include Patrick J. Zenner, Chairman; Peter S. Lawrence, President and Chief Operating Officer and 8 others. See the full leadership team at …See details»
Merck Completes Acquisition of ArQule - Nasdaq
Jan 16, 2020 Merck, known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the …See details»
Merck to Acquire ArQule, Advancing Leadership in Oncology
Dec 9, 2019 Under the terms of the acquisition agreement announced today, Merck, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of ArQule. The closing of …See details»
Merck Completes Acquisition of ArQule - s2.q4cdn.com
Following the completion of the tender o er, Merck completed the acquisition of ArQule today through a merger of Merck’s wholly-owned subsidiary with and into ArQule in which all shares …See details»
Merck Completes Acquisition of ArQule - Business Wire
Jan 16, 2020 Following the completion of the tender offer, Merck completed the acquisition of ArQule today through a merger of Merck’s wholly-owned subsidiary with and into ArQule in …See details»
ArQule wanted a partner. Merck wanted control. Solution? A …
Dec 19, 2019 It’s not uncommon for partnership talks focused on one drug to escalate into a full-on buyout. And that's just what happened with Merck & Co.’s $2.7 billion deal for ArQule.See details»
ArQule Inc. - The New York Times
Patents; A company finds a new way for medicinal chemists to test experimental drug formulations. Arqule Inc receives patent for parallel synthesis, which uses robotic work stations …See details»
Merck to Acquire ArQule, Advancing Leadership in Oncology
Dec 9, 2019 KENILWORTH, N.J.& BURLINGTON, Mass.---- Merck, known as MSD outside the United States and Canada, and ArQule, Inc. today announced that the companies have …See details»
Merck to Acquire ArQule, Advancing Leadership in Oncology
KENILWORTH, N.J. & BURLINGTON, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and ArQule, Inc. (Nasdaq: ARQL) today …See details»
Access Funding - ARCQE
Professional Development Funding ARCQE is pleased to offer a variety of Professional Development (PD) opportunities for Early Childhood Educators inclusive for early learning and …See details»
Estampación, Foils, Etiquetas Textiles, RFID, España
Comercial Arque trabaja en el Suministro para Estampación, TTR, Foils, Películas, Escarcha, Ribbon, Etiquetas, Soportes Textiles, RFID y Impak en España.See details»